Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer

ABSTRACT #9003 HOUSTON – Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University…

Details